Pfizer to Close Neusentis Development Unit in UK
Pfizer plans to close its Neusentis development unit in the UK, a move that will affect up to 120 jobs, the company says.
After consolidating its neuroscience and pain research units, the company decided to concentrate on neuroscience programs that will make the biggest difference in patients’ lives, such as Parkinson’s, Alzheimer’s and Huntington’s disease, Pfizer spokesman Dean Mastrojohn said.
Pfizer will continue to advance late-stage pain programs such as its chronic pain treatment tanezumab, in partnership with Eli Lilly, Mastrojohn says.
The decision to close the site is subject to completion of the “Colleague Forum consultation process and other requirements of local law,” he adds.
The spokesman did not say whether the move was related to Pfizer’s proposed $160 billion merger with Dublin-based Allergan.